For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on March 13th, 2024 | 06:30 CET
Bayer disappoints, BioNTech share gives hope, and Cardiol Therapeutics with upside potential!
Analysts were anticipating a more favourable outcome from Bayer's Capital Markets Day. While the spin-off of Aspirin and Co. was expected, and there was also more transparency in the legal disputes, the actual results differed significantly. In some cases, analysts' share price targets plummeted by nearly 50%. In contrast, analysts have renewed their "Buy" recommendation for Cardiol Therapeutics shares. The specialist in cardiovascular diseases is facing exciting weeks and the share could certainly still more than double. There is also movement at BioNTech. In addition to operating figures, there will soon be an update on the drug pipeline. The question remains whether the share can halt its downward trend.
Read
Commented by Fabian Lorenz on March 7th, 2024 | 06:45 CET
Buy recommendations for TUI and Saturn Oil + Gas share - Aixtron share price targets tumble
TUI was among the daily winners yesterday. The tourism group's share price rose by more than 5%. The reason was positive analyst commentary. The price target was raised, providing significant upside potential from the current level. Experts also recommend buying Saturn Oil & Gas. After a successful capital increase, the target price for the oil producer's shares was raised. Analysts see over 100% upside potential and scope for high dividends. At Aixtron, analysts' price targets are tumbling. There is even a sell recommendation. However, not all analysts are pessimistic; some see an opportunity in the price slide of the past few days.
Read
Commented by Fabian Lorenz on March 6th, 2024 | 11:30 CET
Hydrogen news: Nel shares "Sell", Thyssenkrupp Nucera "Buy", and First Hydrogen convinces customers
Are Nel shares at risk of another price slide? The Norwegians failed to impress with their figures for the fourth quarter and the full year 2023. Incoming orders, in particular, are a cause for concern. Analysts see further downside potential for the share, but there are also optimists. In contrast, the hydrogen newcomer First Hydrogen, which specializes in commercial vehicles, is convincing. In the UK, there was no loss of range even during use in the cold season. Owners of Tesla, Volkswagen and the like can only dream of this. If concrete orders follow, the share should be able to take off. Analysts see potential for Thyssekrupp Nucera shares. The development in the first quarter was convincing. However, investors should also scrutinize the developments in the German hydrogen hopeful.
Read
Commented by Fabian Lorenz on February 29th, 2024 | 08:00 CET
Renk, Hensoldt and Desert Gold: Price gains with armaments and gold
German defense stocks are currently in high demand. Rheinmetall shares have already gained 40% in the current year, while Hensoldt achieved a performance of 35% in the first two months of 2024. The figures for 2023 only dampened the mood briefly. What do analysts say about Hensoldt's share price potential? Stock market newcomer Renk still has to establish itself. But the IPO is beginning to bear fruit. Gold shares should also benefit from the global uncertainties. However, the performance of Barrick & Co. in recent years has been disappointing. Desert Gold could become the surprise stock of the year. According to experts, the explorer was the talk of the town at the recently concluded Mining INDABA trade fair in Cape Town, South Africa.
Read
Commented by Fabian Lorenz on February 28th, 2024 | 07:45 CET
Strong price targets! Super Micro Computer, Bayer, Almonty Industries
Is it time to invest in Super Micro now? Yes, say several experts. Despite the massive price rally, the AI share offers further potential. There are good reasons for this, and the target price is USD 1,300. There are also good reasons for the Almonty Industries share to perform well in 2024 and beyond. The Company focuses on tungsten, a scarce and coveted resource in Europe and North America. Sales and profits are expected to rise sharply, leading to a revaluation of the share. Analysts also see significant potential for Bayer shares. The spin-off of over-the-counter medications, including Aspirin, is expected to drive the share. However, there are some question marks.
Read
Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET
Top news: BYD, Bayer and Globex Mining
Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.
Read
Commented by Fabian Lorenz on February 20th, 2024 | 08:00 CET
Sell Varta shares? Nel and Altech Advanced Materials with new opportunities
The bad news for Varta seems to be unending. First, a cyber attack paralyzed the Company. Now, analysts are lowering their thumbs and recommending selling the share. Estimates for the years 2024 and 2025 have been lowered. As a result, Altech Advanced is increasingly becoming the German battery hopeful. Even though Altech's share price has declined significantly in recent months, the Company is on track operationally. The current year will be exciting. Things also remain exciting for hydrogen shares. While Nel and Plug Power & Co. still need to prove the future viability of their business models, they are receiving billions in support.
Read
Commented by Fabian Lorenz on February 15th, 2024 | 07:15 CET
The Nel share is tumbling, Nordex is gaining momentum, and dynaCERT is building strength
Is there a 70% upside potential in the Nordex share? This is what analysts are suggesting based on the convincing preliminary figures. But is this development sustainable? Shareholders are hoping for convincing quarterly figures from Nel, even though no major orders have been reported for some time. The share is in a clear downward trend, and analysts have recently drastically reduced the price target for the hydrogen pure-play. While the shares of Nel, Plug Power & Co. are stumbling, dynaCERT is showing relative strength. In an industry environment that is anything but positive, the shares of the Canadian hydrogen company are forming a base.
Read
Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET
Plug Power, Bayer, Defense Metals: Shares in panic mode
Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.
Read
Commented by Fabian Lorenz on February 7th, 2024 | 07:30 CET
BASF shares on the upswing, BioNTech sees breakthrough in cancer, and Defence Therapeutics benefits from study
Can BASF shareholders look forward to better times? One analyst is certainly hopeful. He believes that the chemical industry will recover in 2024. However, the price target gives pause for thought. The development of cervical cancer is also concerning. According to a new study, the number of cases has risen sharply in recent years, and with it, HPV infections. Accordingly, more HPV vaccines are urgently needed. The market volume is expected to more than double to over USD 15 billion in just a few years. Defence Therapeutics aims to become a profiteer. The biotech company is fighting cancer with its Accum™ platform. BioNTech CEO Ugur Sahin also believes that humanity will get cancer under control, thanks in part to artificial intelligence. The Company is currently working on 30 cancer therapies. Is it a good time to invest now?
Read